相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The Pediatric COVID Outcomes Study (PECOS), a collaboration between Children's National Hospital and the NIH, prospectively followed over 1,000 children to characterize COVID-19's lasting effects. - Researchers identified 20 symptoms more common in infected children, including fatigue, headaches, GI problems, and cognitive difficulties, with presentations varying by age and evolving over time. - Advanced cardiac testing found no lasting heart damage in children, even among those reporting chest pain or racing heartbeats, providing reassurance to families. - Investigators call for recognizing infection-associated chronic illness as a clinical category and applying resources to children equally as to adults.
- The ReMIND phase 1 trial demonstrated that multi-antigen-targeting TAA-T cell therapy is feasible and well tolerated in pediatric patients with DIPG and relapsed CNS tumors, with 88% of adverse events being low grade. - Three proteins — WT1, PRAME, and survivin — were targeted simultaneously, and the maximum tolerated dose was established at 8 × 10⁷ cells/m² per dose for future phase 2 studies. - Among relapsed/refractory patients, median overall survival post-infusion was 12.7 months, with one patient remaining in complete response over 3 years and others disease-free beyond 4 years. - Unlike CAR-T therapies, this non-genetically modified autologous T cell approach was associated with minimal severe inflammatory toxicity, with only one case of grade 1 cytokine release syndrome observed.
- Children with five genetic subtypes of short stature experienced significant growth acceleration from 4.53 cm/year to 8.09 cm/year during vosoritide treatment in a phase 2 basket trial. - The study represents the first precision medicine approach for MAPK pathway growth disorders, with NPR2 deficiency patients showing particularly robust responses without significant adverse events. - Long-term safety concerns emerged as five participants discontinued treatment due to orthopedic complications including slipped capital femoral epiphyses and severe genu valgum, particularly in children with ACAN mutations. - The trial demonstrates potential for expanding vosoritide use beyond its current achondroplasia indication, though careful monitoring is essential for certain genetic subtypes.
- A leading mid-Atlantic health insurer has published a new coverage policy for the Nerivio REN wearable, granting reimbursed access to approximately 3.4 million members in Maryland, Washington D.C., and Northern Virginia. - The policy recognizes Nerivio as medically necessary for both acute and preventive migraine treatment in patients ages 8 and older, making it the first non-pharmacological migraine treatment covered by this provider. - With this expansion, approximately 85 million lives across the U.S. now have coverage for Nerivio, supported by 25 peer-reviewed studies demonstrating the device's clinical efficacy. - A separate study published in the Journal of Clinical Medicine confirms that Nerivio can be safely used simultaneously with continuous glucose monitoring devices, addressing safety concerns for patients with comorbid diabetes and migraine.
- St. Jude researchers analyzed data from nearly 900 pediatric medulloblastoma patients across three clinical trials to develop new treatment risk groups that could safely reduce therapy intensity. - The study found that 40% of medulloblastoma patients can receive lower doses of craniospinal radiation therapy and almost all can receive less chemotherapy while maintaining equivalent survival outcomes. - Scientists created the Medulloblastoma Meta-Analysis Portal, a web-based tool that allows physicians to predict patient outcomes using demographic, clinical and molecular features through a point-and-click interface. - The research identified four actionable treatment recommendation groups based on molecular features including chromosome alterations, methylation subgroups and MYC oncogene amplifications in G3 and G4 tumor types.
- A comprehensive meta-analysis of 243 patients demonstrates that the Tafinlar-Mekinist combination achieves significant response rates in both pediatric (53%) and adult (39%) glioma patients. - The drug combination shows comparable safety profiles between age groups, with pooled side effect rates of 96% in pediatric and 83% in adult patients, though the difference was not statistically significant. - The FDA's March 2023 approval of Tafinlar-Mekinist for BRAF V600E low-grade gliomas marks the first systemic therapy approval for pediatric brain cancer patients aged one and older.
- A recent study in _JAMA Network Open_ found no increased risk of major congenital malformations (MCMs) in infants exposed to tetracyclines during the first trimester. - The population-based cohort study analyzed data from over 1.2 million children in Sweden, comparing MCM rates in tetracycline-exposed and unexposed infants. - Researchers found no significant difference in the risk of MCMs, including heart defects and neural tube defects, between the two groups. - Experts emphasize the need for more research on drug safety during pregnancy, as pregnant individuals are often excluded from clinical trials.
